PHP
STOK icon

Parkman Healthcare Partners’s Stoke Therapeutics STOK Stock Holding History

Parkman Healthcare Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Sell
336,519
-93,636
-22% -$3.07M 1.13% 30
2025
Q4 		$13.7M Buy
430,155
+180,155
+72% +$5.42M 1.3% 24
2025
Q3 		$5.88M Buy
+250,000
New +$4.28M 0.61% 59

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Parkman Healthcare Partners's STOK Position: Q1 2026 in Review

Parkman Healthcare Partners reduced its Stoke Therapeutics (STOK) stake by 22% in Q1 2026, selling an estimated $3.07M and leaving 336,519 shares worth $11M. The position accounts for 1.13% of the portfolio, ranked #30.

Parkman Healthcare Partners first reported a position in STOK in Q3 2025 and has held it in 3 quarters since. The position peaked at $13.7M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Parkman Healthcare Partners held 336,519 shares of Stoke Therapeutics worth $11M as of Q1 2026.
  • Parkman Healthcare Partners sold 93,636 Stoke Therapeutics shares in Q1 2026, an estimated $3.07M.
  • Stoke Therapeutics made up 1.13% of Parkman Healthcare Partners's portfolio in Q1 2026, its #30 holding.
  • Parkman Healthcare Partners first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Parkman Healthcare Partners's Stoke Therapeutics position peaked at $13.7M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.